

Semaglutide reduces risk of cardiovascular events in patients with type 2 diabetes, finds study

Semaglutide, used as an anti-diabetic and anti-obesity medication, can cut the risks of heart attacks, strokes and cardiovascular disease by 14%, the international study, of which India was a part, found



Diabetes management shouldn't be focused narrowly on blood sugar levels, but must concurrently work at protecting cardiac and renal health too, states a recent study that found daily oral semaglutide (an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management) could cut the risk of heart attacks, strokes and cardiovascular death by 14%.

In a phase three trial of people with diabetes, the study, called SOUL, tested Rybelsus - Novo Nordisk's diabetes drug administered in oral form - against a placebo, in trial participants already receiving standard medications.

News Source:

<https://www.thehindu.com/sci-tech/health/semaglutide-reduces-risk-of-cardiovascular-events-in-patients-with-type-2-diabetes-finds-study/article69415845.ece>